Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/17/18Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple SclerosisPrinter Friendly Version
11/30/18Statement by Richard Pops, Chairman and CEO of Alkermes on the Annual CDC Report on Drug Overdose Deaths and Suicide Mortality in the United StatesPrinter Friendly Version
11/29/18Alkermes Announces Positive Topline Results From ENLIGHTEN-2 Phase 3 Study of ALKS 3831 in Patients With SchizophreniaPrinter Friendly Version
11/06/18Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare ConferencesPrinter Friendly Version
11/06/18Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual MeetingPrinter Friendly Version
11/01/18Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive DisorderPrinter Friendly Version
11/01/18Trading in Alkermes Ordinary Shares Halted TodayPrinter Friendly Version
10/29/18Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular PsychiatryPrinter Friendly Version
10/26/18Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS®Printer Friendly Version
10/23/18Alkermes Plc Reports Third Quarter 2018 Financial ResultsPrinter Friendly Version
10/17/18Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych CongressPrinter Friendly Version
10/16/18Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial ResultsPrinter Friendly Version
09/10/18Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor PembrolizumabPrinter Friendly Version
09/05/18Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use DisordersPrinter Friendly Version
08/01/18Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth ConferencePrinter Friendly Version
07/26/18Alkermes Plc Reports Second Quarter 2018 Financial ResultsPrinter Friendly Version
07/19/18Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial ResultsPrinter Friendly Version
07/02/18FDA Approves ARISTADA INITIO™ for the Initiation of ARISTADA® for SchizophreniaPrinter Friendly Version
06/06/18Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare ConferencePrinter Friendly Version
06/06/18Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development ProgramPrinter Friendly Version
05/29/18Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare ConferencePrinter Friendly Version
05/23/18Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual MeetingPrinter Friendly Version
05/14/18Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare ConferencePrinter Friendly Version
05/10/18Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care ConferencePrinter Friendly Version
05/04/18Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders ResearchPrinter Friendly Version
05/03/18Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development ProgramPrinter Friendly Version
05/02/18Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care ConferencePrinter Friendly Version
04/30/18Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual MeetingPrinter Friendly Version
04/26/18Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for SchizophreniaPrinter Friendly Version
04/26/18Alkermes Plc Reports First Quarter 2018 Financial ResultsPrinter Friendly Version
04/19/18Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial ResultsPrinter Friendly Version
04/16/18Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive DisorderPrinter Friendly Version
04/02/18Alkermes Receives Refusal to File Letter From FDA for ALKS 5461Printer Friendly Version
03/05/18Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare ConferencesPrinter Friendly Version
03/01/18Alkermes Appoints James Robinson as President and Chief Operating OfficerPrinter Friendly Version
02/14/18Alkermes Appoints Shane Cooke to Board of DirectorsPrinter Friendly Version
02/14/18Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018Printer Friendly Version
02/07/18Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial ResultsPrinter Friendly Version
01/31/18Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive DisorderPrinter Friendly Version
01/02/18Alkermes' Corporate Presentation to be Webcast at the 36th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version

Other Resources

Email Alerts

Stay in Touch with Alkermes